Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation

Journal of Medical Virology

Volumn 74, Issue 2, 2004, Pages 336-343

  Saito, Takehiko ^a   Nakaya, Yoko ^a   Suzuki, Takashi ^b   Ito, Reiko ^a   Saito, Toshinori ^a   Saito, Hiroyuki ^c   Takao, Shinichi ^d   Sahara, Keiji ^e   Odagiri, Takato ^a   Murata, Takeomi ^f   Usui, Taichi ^f   Suzuki, Yasuo ^b   Tashiro, Masato ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c Akita Prefectural Institute of Public Health   (Japan)

^d Hiroshima Prefectural Univ   (Japan)

^e SHIZUOKA INSTITUTE OF ENVIRONMENT AND HYGIENE   (Japan)

^f SHIZUOKA UNIVERSITY   (Japan)

Author keywords

Carbohydrate; Embryonated eggs; MDCK cells; Surveillance

Indexed keywords

HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE; SIALIC ACID; VIRUS HEMAGGLUTININ; VIRUS PROTEIN; VIRUS VACCINE;

ADAPTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; BINDING AFFINITY; CLONE; CONTROLLED STUDY; HAMSTER; IMMUNOGENICITY; INFLUENZA VIRUS B; MOLECULAR CLONING; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN GLYCOSYLATION; VIRUS CELL INTERACTION; VIRUS INACTIVATION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENIC VARIATION; ANTIGENS, VIRAL; CELL LINE; CELLS, CULTURED; CHICK EMBRYO; CRICETINAE; DOGS; GLYCOSYLATION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE INFECTIONS; SEQUENCE ANALYSIS, DNA; VIRUS CULTIVATION;

CRICETINAE; GALLUS GALLUS; INFLUENZA B VIRUS; INFLUENZA VIRUS;

EID: 4344676784     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20178     Document Type: Article

References (31)

1. Alymova IV, Kodihalli S, Govorkova EA, Fanget B, Gerdil C, Webster RG. 1998. Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs. J Virol 72:4472-4477.
2. Beebe DP, Schreiber RD, Cooper NR. 1983. Neutralization of influenza virus by normal human sera: Mechanisms involving antibody and complement. J Immunol 130:1317-1322.
3. Berton MT, Naeve CW, Webster RG. 1984. Antigenic structure of the influenza B virus hemagglutinin: Nucleotide sequence analysis of antigenic variants selected with monoclonal antibodies. J Virol 52:919-927.
4. Feng JQ, Mozdzanowska K, Gerhard W. 2002. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 76:1369-1378.
5. Gambaryan AS, Matrosovich MN. 1992. A solid-phase enzyme-linked assay for influenza virus receptor-binding activity. J Virol Methods 39:111-123.
6. Gambaryan AS, Robertson JS, Matrosovich MN. 1999. Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Virology 258:232-239.
7. Gubareva LV, Wood JM, Meyer WJ, Katz JM, Robertson JS, Major D, Webster RG. 1994. Codominant mixtures of viruses in reference strains of influenza virus due to host cell variation. Virology 199:89-97.
8. Imai M, Sugimoto K, Okazaki K, Kida H. 1998. Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin. Virus Res 53:129-139.
9. Katz JM, Webster RG. 1989. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 160:191-198.
10. Katz JM, Naeve CW, Webster RG. 1987. Host cell-mediated variation in H3N2 influenza viruses. Virology 156:386-395.
11. Kida H, Yoden S, Kuwabara M, Yanagawa R. 1985. Interference with a conformational change in the haemagglutinin molecule of influenza virus by antibodies as a possible neutralization mechanism. Vaccine 3:219-222.
12. Kilbourne ED. 1976. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. J Infect Dis 134:384-394.
13. Matrosovich MN, Gambaryan AS, Tuzikov AB, Byramova NE, Mochalova LV, Golbraikh AA, Shenderovich MD, Finne J, Bovin NV. 1993. Probing of the receptor-binding sites of the H1 and H3 influenza A and influenza B virus hemagglutinins by synthetic and natural sialosides. Virology 196:111-121.
14. Meyer WJ, Wood JM, Major D, Robertson JS, Webster RG, Katz JM. 1993. Influence of host cell-mediated variation on the international surveillance of influenza A (H3N2) viruses. Virology 196:130-137.
15. Mozdzanowska K, Furchner M, Washko G, Mozdzanowski J, Gerhard W. 1997. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 71: 4347-4355.
16. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157-1163.
17. Ohuchi M, Ohuchi R, Sakai T, Matsumoto A. 2002. Tight binding of influenza virus hemagglutinin to its receptor interferes with fusion pore dilation. J Virol 76:12405-12413.
18. Oxford JS, Corcoran T, Knott R, Bates J, Bartolomei O, Major D, Newman RW, Yates P, Robertson J, Webster RG, Schild GC. 1987. Serological studies with influenza A(H1N1) viruses cultivated in eggs or in a canine kidney cell line (MDCK). Bull World Health Organ 65:181-187.
19. Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC. 1985. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 143:166-174.
20. Robertson JS, Bootman JS, Newman R, Oxford JS, Daniels RS, Webster RG, Schild GC. 1987. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology 160:31-37.
21. Robertson JS, Nicolson C, Bootman JS, Major D, Robertson EW, Wood JM. 1991. Sequence analysis of the haemagglutinin (HA) of influenza A (H1N1) viruses present in clinical material and comparison with the HA of laboratory-derived virus. J Gen Virol 72:2671-2677.
22. Saito T, Lim W, Suzuki T, Suzuki Y, Kida H, Nishimura SI, Tashiro M. 2001. Characterization of a human H9N2 influenza virus isolated in Hong Kong. Vaccine 20:125-133.
23. Schild GC, Oxford JS, de Jong JC, Webster RG. 1983. Evidence for host-cell selection of influenza virus antigenic variants. Nature 303:706-709.
24. Suzuki T, Jyono M, Tsukimoto M, Hamaoka A, Suzuki Y. 1995. Labeling of influenza virus with alkylamine-modified horseradish peroxidase. Anal Biochem 228:42-47.
25. Totani K, Kubota T, Kuroda T, Murata T, Hidari KI, Suzuki T, Suzuki Y, Kobayashi K, Ashida H, Yamamoto K, Usui T. 2003. Chemoenzymatic synthesis and application of glycopolymers containing multivalent sialyloligosaccharides with a poly (L-glutamic acid) backbone for inhibition of infection by influenza viruses. Glycobiology 13:315-326.
26. WHO. 1992. Standardization and improvement of influenza surveillance: Memorandum from a WHO/GEIG meeting. Bull World Health Organ 70:23-25.
27. WHO. 2001. Influenza in the world. 1 October 2000-30 September 2001. Wkly Epidemiol Rec 76:357-364.
28. WHO. 2003. Recommended composition of influenza virus vaccines for use in the 2003-2004 influenza season. Wkly Epidemiol Rec 78:58-62.
29. Wiley DC, Wilson IA, Skehel JJ. 1981. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289:373-378.
30. Wood JM, Oxford JS, Dunleavy U, Newman RW, Major D, Robertson JS. 1989. Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule. Virology 171:214-221.
31. Wright PF, Webster RG. 2001. Orthomyxoviruses. In: Knipe DM, Howley PM, editors. Fields virology, 4th edn. Philadelphia: Lipincott-Raven. pp 1533-1579.